Labcorp (NYSE: LH) CEO Adam Schechter receives new stock option and RSU awards

Q: How many stock options were granted to the Labcorp (LH) CEO on February 10, 2026?

Adam H. Schechter was granted 31,700 non-qualified stock options . These options carry an exercise price of $284.50 per share, vest in three equal annual installments starting on the grant date, and expire on February 9, 2036, aligning his incentives with long-term shareholder value.

Q: What Restricted Stock Units were awarded to Adam H. Schechter in this Labcorp (LH) Form 4?

Schechter received 10,440 Restricted Stock Units (RSUs) on February 10, 2026. Each RSU represents the contingent right to one share of Labcorp common stock and vests in three equal annual installments beginning on February 10, 2027, subject to continued service and plan terms.

Q: Under which plan were the new stock options granted to the Labcorp (LH) CEO?

The non-qualified stock options were granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan . This plan governs equity-based awards such as options and RSUs, designed to reward executives and other participants for long-term performance and retention.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Labcorp Holdings Inc. reported that its President, CEO and director Adam H. Schechter received new equity awards on February 10, 2026. He was granted 31,700 non-qualified stock options with a $284.50 exercise price, vesting in three equal annual installments and expiring in 2036.

He also received 10,440 Restricted Stock Units (RSUs), each representing one share of Labcorp common stock, which vest in three equal annual installments beginning on February 10, 2027. Following this grant, he holds an aggregate of 25,870 RSUs.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Schechter Adam H

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Non-qualified Stock Options	31,700	$0.00	--
Grant/Award	Restricted Stock Unit	10,440	$0.00	--

Holdings After Transaction: Non-qualified Stock Options — 31,700 shares (Direct); Restricted Stock Unit — 25,870 shares (Direct)

Footnotes (1)

Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. The option vests in three equal annual installments beginning on the date reflected in this column. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

Form 4 Insider Transactions: What Each Field Means →

02/12/2026 - 03:45 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schechter Adam H

(Last)

(First)

(Middle)

531 SOUTH SPRING STREET

(Street)

BURLINGTON

27215

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
LABCORP HOLDINGS INC. [ LH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-qualified Stock Options⁽¹⁾	$284.5	02/10/2026		A		31,700		02/10/2027⁽²⁾	02/09/2036	Common Stock	31,700	$0	31,700	D
Restricted Stock Unit	⁽³⁾	02/10/2026		A		10,440		⁽⁴⁾	⁽⁴⁾	Common Stock	10,440	$0	25,870⁽⁵⁾	D

Explanation of Responses:

1. Employee stock option (right to buy) granted pursuant to the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan.

2. The option vests in three equal annual installments beginning on the date reflected in this column.

3. Each Restricted Stock Unit represents the contingent right to receive one share of Labcorp Holdings Inc. Common Stock.

4. The Restricted Stock Units vest in three equal annual installments beginning on February 10, 2027.

5. This number reflects the aggregate number of Restricted Stock Units held by the reporting person.

	/s/ Kathryn W. Kyle, Attorney-in-Fact for Adam H. Schechter	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Labcorp (LH) report for Adam H. Schechter?

Labcorp reported equity awards to President and CEO Adam H. Schechter. On February 10, 2026, he received grants of non-qualified stock options and Restricted Stock Units as part of the company’s 2025 Omnibus Incentive Plan, increasing his derivative-based exposure to Labcorp common stock.

How many stock options were granted to the Labcorp (LH) CEO on February 10, 2026?

Adam H. Schechter was granted 31,700 non-qualified stock options. These options carry an exercise price of $284.50 per share, vest in three equal annual installments starting on the grant date, and expire on February 9, 2036, aligning his incentives with long-term shareholder value.

What Restricted Stock Units were awarded to Adam H. Schechter in this Labcorp (LH) Form 4?

Schechter received 10,440 Restricted Stock Units (RSUs) on February 10, 2026. Each RSU represents the contingent right to one share of Labcorp common stock and vests in three equal annual installments beginning on February 10, 2027, subject to continued service and plan terms.

What is Adam H. Schechter’s total RSU holding at Labcorp (LH) after this grant?

After the February 10, 2026 award, Schechter holds an aggregate of 25,870 Restricted Stock Units. This figure reflects all RSUs credited to him under Labcorp’s equity plans, providing additional long-term, share-based compensation exposure beyond his stock options.

Under which plan were the new stock options granted to the Labcorp (LH) CEO?

The non-qualified stock options were granted under the Labcorp Holdings Inc. 2025 Omnibus Incentive Plan. This plan governs equity-based awards such as options and RSUs, designed to reward executives and other participants for long-term performance and retention.

How do the vesting schedules work for the Labcorp (LH) CEO’s new equity awards?

The stock options vest in three equal annual installments starting on February 10, 2026. The RSUs vest in three equal annual installments beginning February 10, 2027. These schedules phase in ownership over time, encouraging multi-year alignment with Labcorp’s performance.